已發(fā)表的部分文獻: 標題:METTL3 promotes colorectal carcinoma progression by regulating the m6A-CRB3-Hippo axis.作者:Pan J, Liu F, Xiao X, Xu R, Dai L, Zhu M, Xu H, Xu Y, Zhao A, Zhou W, Dang Y, Ji G;雜志名稱:J Exp Clin Cancer Res 標題:Levels and clinical significance of the m6A methyltransferase METTL14 in patients with coronary heart disease.作者:Guo F, He M, Hu B, Li G;雜志名稱:Front Cardiovasc Med 標題:Effects of Gestational Arsenic Exposures on Placental and Fetal Development in Mice: The Role of Cyr61 m6A.作者:Song YP, Lv JW, Zhang ZC, Qian QH, Fan YJ, Chen DZ, Zhang H, Xu FX, Zhang C, Huang Y, Wang H, Wei W, Xu DX;雜志名稱:Environ Health Perspect 標題:20(S)-ginsenoside Rh2 ameliorates ATRA resistance in APL by modulating lactylation-driven METTL3.作者:Cheng S, Chen L, Ying J, Wang Y, Jiang W, Zhang Q, Zhang H, Wang J, Wang C, Wu H, Ye J, Zhang L;雜志名稱:J Ginseng Res 標題:RNA m6A methylation regulatory mechanism of resveratrol in premature senescence cells.作者:Zhang X, Zhu C, Zhang L, Tan L, Cheng W, Li M, Zhang X, Zhang W, Zhang W;雜志名稱:Food Sci Nutr Epigentek 公司是全球領(lǐng)先的表觀遺傳學相關(guān)研究的技術(shù)創(chuàng)新者和產(chǎn)品開發(fā)供應(yīng)商。開發(fā)了超過700多個專利產(chǎn)品,為表觀遺傳學方面的研究和新藥研發(fā)提供全面系統(tǒng)的解決方案,涵蓋樣品制備、DNA/RNA甲基化(5-mc, 5-hmc, 5-fc, m6A)/DNMT分析、ChIP、組蛋白甲基化/乙酰化/去乙酰化/磷酸化/SUMO-等領(lǐng)域,提供小分子抑制劑、蛋白質(zhì)、抗體、以及分析試劑盒產(chǎn)品。